
Supplemental Figure 1: Dasatinib does not enhance BRAFi/MEKi efficacy in therapy naïve setting. (**A**) The therapy naïve PDX model WM4237-1 was implanted s.q. into an NSG mouse. Treatment with vehicle control, dasatinib, BRAFi/MEKi, or dasatinib + BRAFi/MEKi began when tumors were palpable (denoted with black arrow).

Supplemental Figure



bioRxiv preprint doi: https://doi.org/10.1101/2023.01.20.524923; this version posted January 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.